Harrow Inc. is an eyecare pharmaceutical company focused on discovering, developing, and commercializing ophthalmic pharmaceutical products for the U.S. market. The company operates through two primary business segments: The Branded segment, which includes FDA-approved ophthalmology pharmaceutical products such as IHEEZO, IOPIDINE, VEVYE, ZERVIATE, MAXITROL, ILEVRO, NEVANAC, VIGAMOX, MAXIDEX, FLAREX, TRIESENCE, and NATACYN; and The ImprimisRx segment, representing its ophthalmology-focused pharmaceutical compounding business. These products address various eye conditions, including pain and inflammation from cataract surgery, bacterial conjunctivitis, inflammatory conditions, fungal infections, and ophthalmic diseases requiring steroid treatment. Founded in 1998 and headquartered in Nashville, Tennessee, Harrow helps eyecare professionals preserve vision by making prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans through its comprehensive portfolio.